ClinicalTrials.gg
CompletedNCT05929651Updated Sep 22, 2025Results posted

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

A Phase 4 interventional study of MenACYW conjugate vaccine in Meningococcal Immunisation and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 2 sites in Argentina. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
12 Months to 23 Months
Sex
All
01

Study summary

This study evaluated the immunogenicity and safety of a single dose of MenQuadfi® administered as a booster vaccine in toddlers 12 - 23 months of age in Argentina who had been primed with at least 1 dose of the quadrivalent meningococcal conjugate vaccines Nimenrix® or Menveo® during infancy to protect against invasive meningococcal disease (IMD).

Participants received a single dose of MenQuadfi® at Visit 1. Participants provided 2 blood samples, one at D01 (Visit 1) pre-vaccination and another at D31 (Visit 2) post-vaccination for the immunogenicity assessments.

Study included 2 visits at D01 (Visit 1) and at D31 (Visit 2), and 1 Telephone call (TC) for safety follow-up at D09 post-study vaccination.

Read the detailed description

Study duration was approximately 30 days (+14 days) per participant

02

Conditions studied

  • Meningococcal Immunisation
  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 12 to 23 months on the day of inclusion
  • Participants who are healthy as determined by medical evaluation including medical history, physical examination, and judgement of the Investigator
  • Received at least one priming dose of licensed Nimenrix® or Menveo® vaccine during infancy before 12 months of age with an interval of at least 2 months between the last vaccination with Nimenrix® or Menveo® and the MenQuadfi® booster dose

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically
  • At high risk for meningococcal infection during the study (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease)
  • Personal history of Guillain-Barré syndrome
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid containing vaccine
  • Known systemic to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) on the day of study intervention administration. Prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
  • Receipt of any vaccine (including COVID-19 vaccines) in the 4 weeks preceding the study intervention administration or planned receipt of any vaccine (including COVID-19 vaccines) in the 4 weeks following the study intervention administration except for influenza vaccination, which may be received at least 2 weeks before or 2 weeks after the study intervention. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination with a Meningococcal C vaccine or Meningococcal B (MenB) vaccine
  • Receipt of immunoglobulins, blood or blood-derived products in the past 3 months
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw

NOTE: The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    MenACYW conjugate vaccine

    participants received a single booster dose of the MenACYW conjugate vaccine with an interval of at least 2 months after the last vaccination with Nimenrix® or Menveo® received during infancy before 12 months of age

    Biological: MenACYW conjugate vaccine

Interventions

  • BiologicalMenACYW conjugate vaccine

    Pharmaceutical form: Liquid solution Route of administration: Intramuscular (IM) injection

    Also known as: MenQuadfi®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  2. Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, Y, and W as Measured by Serum Bactericidal Assay Using Human Complement

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA).

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  3. Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 Against Meningococcal Serogroups A, C, Y, and W

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  4. Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=4-Fold Rise From Pre-vaccination to Post-Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  5. Percentage of Participants With Vaccine Seroresponse by Serum Bactericidal Assay Using Human Complement

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). hSBA vaccine seroresponse was defined for a participant with a pre-vaccination titer \<1:8 as a post-vaccination titer of \>=1:16 and for a participant with a pre-vaccination titer \>=1:8 as a post-vaccination titer that is at least 4-fold greater than the pre-vaccination titer. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post vaccination on Day 1)

  6. Geometric Mean Titers Against Meningococcal Serogroups A, C, Y, and W as Measured by Serum Bactericidal Antibody Assay Using Baby Rabbit Complement (rSBA)

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA).

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  7. Percentage of Participants With Serum Bactericidal Antibody Assay Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  8. Percentage of Participants With Serum Bactericidal Antibody Assay Using Baby Rabbit Complement Antibody Titers >=4-Fold Rise From Pre-vaccination to Post-Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  9. Percentage of Participants With Vaccine Seroresponse by Serum Bactericidal Antibody Assay Using Baby Rabbit Complement

    Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). rSBA vaccine seroresponse was defined for a participant with a pre-vaccination titer \<1:8 as a post-vaccination titer of \>=1:32 and for a participant with a pre-vaccination titer \>=1:8 as a post-vaccination titer that is at least 4-fold greater than the pre-vaccination titer. Percentages are rounded to the nearest tenth.

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  10. Geometric Mean Concentrations (GMCs) of Antibodies Against Tetanus Toxoid

    Geometric Mean Concentrations (GMCs) of anti-tetanus toxoid antibodies was measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent assay.

    Time frame: Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)

  11. Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

    An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

    Time frame: Up to 30 minutes post-vaccination on Day 1

  12. Number of Participants With Solicited Injection Site Reactions and Systemic Reactions

    A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited injection site reactions included injection site tenderness, injection site erythema and injection site swelling. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss and irritability.

    Time frame: Up to 7 days post-vaccination on Day 1

  13. Number of Participants With Unsolicited Adverse Events

    An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.

    Time frame: Up to 30 days post-vaccination on Day 1

  14. Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

    An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate.

    Time frame: From vaccination (Day 1) up to 30 days post vaccination, 31 days

07

Results

Posted Sep 22, 2025

Participant flow

This study was conducted at 2 investigational sites in Argentina between 07 September 2023 to 09 September 2024.

Participant flow — Overall Study
MilestoneMenACYW Conjugate Vaccine
Started71
Safety analysis set (safas)69
Completed68
Not completed3
Withdrew: Protocol deviation1
Withdrew: Withdrawal by participant's parents/legally acceptable representatives2

Outcome measures

PrimaryPercentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W
Percentage of participantsMenACYW Conjugate Vaccine
Serogroup A: Day 172.1 (59.2 to 82.9)
Serogroup A: Day 31100 (93.8 to 100)
Serogroup C: Day 160.3 (47.2 to 72.4)
Serogroup C: Day 31100 (94.1 to 100)
Serogroup Y: Day 167.7 (54.7 to 79.1)
Serogroup Y: Day 31100 (93.2 to 100)
Serogroup W: Day 173.4 (60.9 to 83.7)
Serogroup W: Day 31100 (93.8 to 100)
PrimaryGeometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, Y, and W as Measured by Serum Bactericidal Assay Using Human Complement

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA).

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMTs) Against Meningococcal Serogroups A, C, Y, and W as Measured by Serum Bactericidal Assay Using Human Complement
TiterMenACYW Conjugate Vaccine
Serogroup A: Day 114.0 (10.1 to 19.4)
Serogroup A: Day 31244 (163 to 366)
Serogroup C: Day 112.3 (8.29 to 18.2)
Serogroup C: Day 311072 (805 to 1426)
Serogroup Y: Day 114.0 (9.70 to 20.2)
Serogroup Y: Day 31945 (683 to 1309)
Serogroup W: Day 116.9 (11.8 to 24.2)
Serogroup W: Day 31953 (712 to 1275)
PrimaryPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 Against Meningococcal Serogroups A, C, Y, and W

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=1:4 Against Meningococcal Serogroups A, C, Y, and W
Percentage of participantsMenACYW Conjugate Vaccine
Serogroup A: Day 196.7 (88.7 to 99.6)
Serogroup A: Day 31100 (93.8 to 100)
Serogroup C: Day 176.2 (63.8 to 86.0)
Serogroup C: Day 31100 (94.1 to 100)
Serogroup Y: Day 185.5 (74.2 to 93.1)
Serogroup Y: Day 31100 (93.2 to 100)
Serogroup W: Day 187.5 (76.8 to 94.4)
Serogroup W: Day 31100 (93.8 to 100)
PrimaryPercentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=4-Fold Rise From Pre-vaccination to Post-Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Bactericidal Assay Using Human Complement Antibody Titers >=4-Fold Rise From Pre-vaccination to Post-Vaccination
Percentage of participantsMenACYW Conjugate Vaccine
Serogroup A91.1 (80.4 to 97.0)
Serogroup C100 (93.9 to 100)
Serogroup Y96.1 (86.5 to 99.5)
Serogroup W100 (93.7 to 100)
PrimaryPercentage of Participants With Vaccine Seroresponse by Serum Bactericidal Assay Using Human Complement

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using human complement (hSBA). hSBA vaccine seroresponse was defined for a participant with a pre-vaccination titer \<1:8 as a post-vaccination titer of \>=1:16 and for a participant with a pre-vaccination titer \>=1:8 as a post-vaccination titer that is at least 4-fold greater than the pre-vaccination titer. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post vaccination on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Vaccine Seroresponse by Serum Bactericidal Assay Using Human Complement
Percentage of participantsMenACYW Conjugate Vaccine
Serogroup A91.1 (80.4 to 97.0)
Serogroup C100 (93.9 to 100)
Serogroup Y96.1 (86.5 to 99.5)
Serogroup W100 (93.7 to 100)
PrimaryGeometric Mean Titers Against Meningococcal Serogroups A, C, Y, and W as Measured by Serum Bactericidal Antibody Assay Using Baby Rabbit Complement (rSBA)

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA).

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Geometric mean · Titer
Geometric Mean Titers Against Meningococcal Serogroups A, C, Y, and W as Measured by Serum Bactericidal Antibody Assay Using Baby Rabbit Complement (rSBA)
TiterMenACYW Conjugate Vaccine
Serogroup A: Day 182.3 (33.3 to 203)
Serogroup A: Day 314715 (3547 to 6268)
Serogroup C: Day 111.6 (6.54 to 20.7)
Serogroup C: Day 313676 (2707 to 4990)
Serogroup Y: Day 130.9 (15.6 to 61.2)
Serogroup Y: Day 315198 (4091 to 6604)
Serogroup W: Day 128.0 (14.7 to 53.5)
Serogroup W: Day 319329 (6627 to 13132)
PrimaryPercentage of Participants With Serum Bactericidal Antibody Assay Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Bactericidal Antibody Assay Using Baby Rabbit Complement Antibody Titers >=1:8 and >=1:128 Against Meningococcal Serogroups A, C, Y, and W
Percentage of participantsMenACYW Conjugate Vaccine
Serogroup A: >=1:8: Day 156.4 (42.3 to 69.7)
Serogroup A: >=1:128: Day 154.5 (40.6 to 68.0)
Serogroup A: >=1:8: Day 31100 (94.4 to 100)
Serogroup A: >=1:128: Day 31100 (94.4 to 100)
Serogroup C: >=1:8: Day 139.3 (27.1 to 52.7)
Serogroup C: >=1:128: Day 124.6 (14.5 to 37.3)
Serogroup C: >=1:8: Day 31100 (94.4 to 100)
Serogroup C: >=1:128: Day 31100 (94.4 to 100)
Serogroup Y: >=1:8: Day 155.9 (42.4 to 68.8)
Serogroup Y: >=1:128: Day 144.1 (31.2 to 57.6)
Serogroup Y: >=1:8: Day 31100 (94.4 to 100)
Serogroup Y: >=1:128: Day 31100 (94.4 to 100)
Serogroup W: >=1:8: Day 161.9 (48.8 to 73.9)
Serogroup W: >=1:128: Day 141.3 (29.0 to 54.4)
Serogroup W: >=1:8: Day 31100 (94.4 to 100)
Serogroup W: >=1:128: Day 31100 (94.4 to 100)
PrimaryPercentage of Participants With Serum Bactericidal Antibody Assay Using Baby Rabbit Complement Antibody Titers >=4-Fold Rise From Pre-vaccination to Post-Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Bactericidal Antibody Assay Using Baby Rabbit Complement Antibody Titers >=4-Fold Rise From Pre-vaccination to Post-Vaccination
Percentage of participantsMenACYW Conjugate Vaccine
Serogroup A83.3 (70.7 to 92.1)
Serogroup C98.3 (91.1 to 100)
Serogroup Y98.3 (90.8 to 100)
Serogroup W100 (94.2 to 100)
PrimaryPercentage of Participants With Vaccine Seroresponse by Serum Bactericidal Antibody Assay Using Baby Rabbit Complement

Functional meningococcal antibody activity against serogroups A, C, Y, and W was measured in a serum bactericidal assay using baby rabbit complement (rSBA). rSBA vaccine seroresponse was defined for a participant with a pre-vaccination titer \<1:8 as a post-vaccination titer of \>=1:32 and for a participant with a pre-vaccination titer \>=1:8 as a post-vaccination titer that is at least 4-fold greater than the pre-vaccination titer. Percentages are rounded to the nearest tenth.

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Number · Percentage of participants
Percentage of Participants With Vaccine Seroresponse by Serum Bactericidal Antibody Assay Using Baby Rabbit Complement
Percentage of participantsMenACYW Conjugate Vaccine
Serogroup A83.3 (70.7 to 92.1)
Serogroup C98.3 (91.1 to 100)
Serogroup Y98.3 (90.8 to 100)
Serogroup W100 (94.2 to 100)
PrimaryGeometric Mean Concentrations (GMCs) of Antibodies Against Tetanus Toxoid

Geometric Mean Concentrations (GMCs) of anti-tetanus toxoid antibodies was measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent assay.

Time frame:
Day 1 (pre-vaccination) and Day 31 (30 days post-vaccination on Day 1)
Reported as:
Geometric mean · International units/milliliter
Geometric Mean Concentrations (GMCs) of Antibodies Against Tetanus Toxoid
International units/milliliterMenACYW Conjugate Vaccine
Day 10.642 (0.482 to 0.854)
Day 318.56 (6.17 to 11.9)
PrimaryNumber of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and onset window post-vaccination.

Time frame:
Up to 30 minutes post-vaccination on Day 1
Reported as:
Count of participants · Participants
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
ParticipantsMenACYW Conjugate Vaccine
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)0
PrimaryNumber of Participants With Solicited Injection Site Reactions and Systemic Reactions

A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF. An injection site reaction was an AR at and around the injection site. Solicited injection site reactions included injection site tenderness, injection site erythema and injection site swelling. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss and irritability.

Time frame:
Up to 7 days post-vaccination on Day 1
Reported as:
Count of participants · Participants
Number of Participants With Solicited Injection Site Reactions and Systemic Reactions
ParticipantsMenACYW Conjugate Vaccine
Solicited injection site reaction24
Solicited systemic reaction35
PrimaryNumber of Participants With Unsolicited Adverse Events

An unsolicited AE was an observed AE that did not fulfill the conditions of solicited reactions, i.e., pre-listed in the CRF in terms of diagnosis and/or onset window post-vaccination.

Time frame:
Up to 30 days post-vaccination on Day 1
Reported as:
Count of participants · Participants
Number of Participants With Unsolicited Adverse Events
ParticipantsMenACYW Conjugate Vaccine
Number of Participants With Unsolicited Adverse Events23
PrimaryNumber of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)

An SAE was any AE that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's study intervention or program, for which ongoing monitoring and rapid communication by the investigator to the Sponsor could be appropriate.

Time frame:
From vaccination (Day 1) up to 30 days post vaccination, 31 days
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
ParticipantsMenACYW Conjugate Vaccine
SAEs1
AESIs1

Adverse events

Collected over AEs, SAEs and all-cause mortality (deaths) were collected from vaccination (Day 1) up to 30 days post vaccination, 31 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MenACYW Conjugate Vaccine0/69 (0%)1/69 (1.4%)45/69 (65.2%)
Most frequent serious events
Most frequent serious events
EventMenACYW Conjugate Vaccine
Febrile ConvulsionNervous system disorders1/69
Most frequent other events
Showing 10 of 11
Most frequent other events
EventMenACYW Conjugate Vaccine
IrritabilityPsychiatric disorders22/69
Injection Site PainGeneral disorders21/69
Decreased AppetiteMetabolism and nutrition disorders14/69
CryingGeneral disorders14/69
PyrexiaGeneral disorders14/69
SomnolenceNervous system disorders13/69
VomitingGastrointestinal disorders13/69
DiarrhoeaGastrointestinal disorders5/69
NasopharyngitisInfections and infestations4/69
Injection Site ErythemaGeneral disorders4/69

Baseline characteristics

Baseline characteristics were evaluated for study participants with data in case report form (CRF).

Age, Continuous
Age, Continuous(months)MenACYW Conjugate Vaccine
Mean14.3 ± 1.50
Sex: Female, Male
Sex: Female, Male(Participants)MenACYW Conjugate Vaccine
Female34
Male37
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)MenACYW Conjugate Vaccine
08

Study locations

2 sites
  • Investigational Site Number : 0320002
    Buenos Aires, Buenos Aires F.D. 1430, Argentina
  • Investigational Site Number : 0320001
    Ciudad Autonoma Buenos Aires, C1425EFD, Argentina
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Sep 2024, 12 months.

Results were first posted in Sep 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2023
First posted
Jul 3, 2023
StartActual
Sep 7, 2023
Primary completionActual
Sep 9, 2024
CompletionActual
Sep 9, 2024
Results first posted
Sep 22, 2025
Last update
Sep 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05929651
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Sep 7, 2023
Primary completion
Sep 9, 2024
Completion
Sep 9, 2024
Results posted
Sep 22, 2025
Last update
Sep 22, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi Pasteur, a Sanofi Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion